ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation

BACKGROUND: Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, yet i...

Descripción completa

Detalles Bibliográficos
Autores principales: Konduri, Kameswari S., Pattisapu, Ram, Pattisapu, Jogi, Konduri, Girija G., Zwetchkenbaum, John, Roy, Bidhan, Barman, Monalisa, Frazier, Adria, Hurst, Brett L., Düzgüneş, Nejat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580381/
https://www.ncbi.nlm.nih.gov/pubmed/34766166
http://dx.doi.org/10.33696/pharmacol.3.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580381/
https://www.ncbi.nlm.nih.gov/pubmed/34766166
http://dx.doi.org/10.33696/pharmacol.3.028

Ejemplares similares